Browse every story filed under this topic, curated from trusted publishers around the world.
A day after the DOJ said it would ease restrictions on medical marijuana, the FDA moves to fast-track some experimental psychedelic drugs for review. They're looking at three drugs for treatment-resistant depression, major depressive disorder, and …
Read full story →
The Food and Drug Administration (FDA) on Friday granted fast-track review to three companies studying psychedelic therapies to treat depression …
The FDA is issuing national priority vouchers to three companies studying psychedelic drugs to treat serious mental illness. The vouchers …
The Food and Drug Administration on Friday granted a quick review of three experimental psychedelic drugs meant to treat major …
The federal government launched a behavioral health research initiative, with $50 million allocated to match state investments in psychedelic research, …
The plant has been hailed as a potential treatment for opioid use disorder.
CAR T cell therapy wipes out rogue antibodies' source and improves walking speed in people with the same autoimmune disorder …
A plant-based psychoactive compound, ibogaine, is making headlines. President Donald Trump signed an executive order to accelerate research, regulatory review …
The era of off-label guesswork for patients living with the rare autoimmune disorder MOGAD may soon be over, as a …
Women experience mental health disorders at significantly higher rates than men. In primary care settings, 43% of women have at …
Former pace bowler Zadran is receiving treatment for HLH, a rare immune system disorder, at a hospital in India.
You've seen all articles for #disorder.
Check back
soon
for new stories.